Acts as a transcriptional repressor. Inhibits interleukin-2 (IL-2) gene expression. Enhances or represses the promoter activity of the ATP1A1 gene depending on the quantity of cDNA and on the cell type. Represses E-cadherin promoter and induces an epithelial-mesenchymal transition (EMT) by recruiting SMARCA4/BRG1. Represses BCL6 transcription in the presence of the corepressor CTBP1. Positively regulates neuronal differentiation. Represses RCOR1 transcription activation during neurogenesis. Represses transcription by binding to the E box (5'-CANNTG-3'). Promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Interacts (via N-terminus) with SMARCA4/BRG1. Colocalizes with SMARCA4/BRG1 in E-cadherin- negative cells from established lines, and stroma of normal colon as well as in de-differentiated epithelial cells at the invasion front of colorectal carcinomas. Expressed in heart and skeletal muscle, but not in liver, spleen, or pancreas. Belongs to the delta-EF1/ZFH-1 C2H2-type zinc-finger family. Note: This description may include information from UniProtKB.
Protein type: Motility/polarity/chemotaxis; C2H2-type zinc finger protein; DNA binding protein; Transcription, coactivator/corepressor
Cellular Component: cytoplasm; nucleolus; nucleus
Molecular Function: protein binding; zinc ion binding; sequence-specific DNA binding; transcription coactivator activity; transcription factor activity; transcription corepressor activity
Biological Process: regulation of transcription from RNA polymerase II promoter; cell proliferation; transcription, DNA-dependent; immune response; negative regulation of transcription from RNA polymerase II promoter; positive regulation of neuron differentiation; negative regulation of transcription, DNA-dependent
SS: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.